Baidu
map

Hepatology:肝细胞癌(HCC)1~2cm不确定结节是否活检?

2012-02-17 MedSci MedSci原创

 加拿大一项研究报告,肝脏1~2cm不确定结节的恶性率较低,对所有这些结节进行活检会导致许多阴性结果,将活检限定于高动脉血供或者同时存在典型HCC的结节则可以检出多数HCC,并且使活检量大大减少。论文发表于《肝脏病学》[Hepatology 2011,54(6):2048]。   该研究连续纳入80例患者共计93个不确定的结节,其中85个结节获得最终诊断,包括13个恶性结节和72个良性结节。通

 加拿大一项研究报告,肝脏1~2cm不确定结节的恶性率较低,对所有这些结节进行活检会导致许多阴性结果,将活检限定于高动脉血供或者同时存在典型HCC的结节则可以检出多数HCC,并且使活检量大大减少。论文发表于《肝脏病学》[Hepatology 2011,54(6):2048]。   该研究连续纳入80例患者共计93个不确定的结节,其中85个结节获得最终诊断,包括13个恶性结节和72个良性结节。通过单变量逻辑分析对肝病病因、患者种族、结节大小、高动脉血供、静脉期强化减弱、同时存在典型HCC等因素进行分析,确定能够预测结节为恶性的显著因素。   结果显示,1~2cm不确定结节的恶性率为14%~23%,只有高动脉血供或者同时存在典型HCC为预测恶性的显著因素,如果只对具有显著因素的结节进行活检,结果会进行23例次活检,可检出13个恶性结节中的8个,敏感度和特异度分别为62%和79%。   主持人点评:单凭小的活检标本对极早期HCC和高度不典型增生进行鉴别诊断非常困难,美国肝病研究学会指南建议对所有不确定的结节进行影像学随访18~24个月。该研究并未对所有结节进行影像学随访,有些随访时间不到18

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863180, encodeId=284a1863180f2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 02 21:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978308, encodeId=1e7419e83081d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 07 11:50:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259464, encodeId=356a125946458, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277925, encodeId=3b9512e792592, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426501, encodeId=2a1e142650182, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-08-02 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1863180, encodeId=284a1863180f2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 02 21:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978308, encodeId=1e7419e83081d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 07 11:50:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259464, encodeId=356a125946458, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277925, encodeId=3b9512e792592, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426501, encodeId=2a1e142650182, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1863180, encodeId=284a1863180f2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 02 21:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978308, encodeId=1e7419e83081d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 07 11:50:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259464, encodeId=356a125946458, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277925, encodeId=3b9512e792592, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426501, encodeId=2a1e142650182, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1863180, encodeId=284a1863180f2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 02 21:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978308, encodeId=1e7419e83081d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 07 11:50:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259464, encodeId=356a125946458, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277925, encodeId=3b9512e792592, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426501, encodeId=2a1e142650182, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 smlt2008
  5. [GetPortalCommentsPageByObjectIdResponse(id=1863180, encodeId=284a1863180f2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Aug 02 21:50:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978308, encodeId=1e7419e83081d, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Aug 07 11:50:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259464, encodeId=356a125946458, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277925, encodeId=3b9512e792592, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426501, encodeId=2a1e142650182, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Feb 19 09:50:00 CST 2012, time=2012-02-19, status=1, ipAttribution=)]
    2012-02-19 gwc384

相关资讯

原发性肝细胞癌普通外科临床路径(2011年版)

 近日,卫生部印发了原发性肝细胞癌普通外科临床路径(2011年版)。   原发性肝细胞癌临床路径   (2011年版)      一、原发性肝细胞癌临床路径标准住院流程   (一)适用对象。   第一诊断为原发性肝细胞癌(ICD-10:C22.0)   行规则性肝切除或非规则性肝切除术(ICD-9-CM-3:50.22/50.3)。   (二)诊断依据。   根据《临床诊疗指南

人类白细胞抗原G蛋白表达是肝细胞癌治愈性切除后的一种不良预后因子

MedSci简评:这篇文章中上海中山医院肝癌研究所的文章,文章并不复杂,主要研究HLA-G对肝癌预后的判断。特色有:(1)选择的是肝癌治愈性切除后的样本;(2)采用了组织芯片技术;(3)样本量较大;(4)研究切入当前的热点如Treg作用。 Human leukocyte antigen-G protein expression is an unfavorable prognostic predi

综合评分可用于对晚期肝细胞癌患者进行分层

  《肿瘤学》(Oncology)杂志近期发表的一项研究结果提示,意大利肝癌计划评分或Okuda评分结合体能状态(PS)可用于对接受索拉菲尼治疗的晚期肝细胞癌(HCC)患者进行分层。   该研究从1个中心收集了201例接受索拉非尼治疗的转移性HCC患者的数据。结果显示,慢性乙型肝炎是肝癌的最主要病因(84%)。 在162例可评估的患者中,4例得到部分缓解。中位随访15.7个月时,中位无

Baidu
map
Baidu
map
Baidu
map